​For dates of service on or after July 11, 2022, Independence will update its medical policies on Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions for Commercial and Medicare Advantage members.

Autologous platelet-rich plasma (PRP) for the treatment of all orthopedic conditions is considered experimental/investigational effective July 11, 2022, for both Commercial and Medicare Advantage members.

For detailed changes, please refer to the Commercial and Medicare Advantage Policy Notifications, which were posted on April 11, 2022.